Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics to Participate in December Investor Conferences
04:00pm, Monday, 02'nd Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following December investor
PDUFA Target Action Date Set for September 26, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug A
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
10:31am, Wednesday, 20'th Nov 2024
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.
Bayer acquires rights to Cytokinetics' heart drug in Japan
03:26am, Tuesday, 19'th Nov 2024
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
02:30am, Tuesday, 19'th Nov 2024
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with Tiered Royalties on Future Sales SOUTH SAN FRANCISCO, Calif. a
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
09:00am, Saturday, 16'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adv
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
07:30am, Monday, 11'th Nov 2024
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (N
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
07:58pm, Wednesday, 06'th Nov 2024
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
06:06pm, Wednesday, 06'th Nov 2024
Cytokinetics (CYTK) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.35 per share a year ago.
Cytokinetics Reports Third Quarter 2024 Financial Results
04:00pm, Wednesday, 06'th Nov 2024
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Exp
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Monday, 04'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it granted stock options to purchase an aggregate of 1
Cytokinetics to Announce Third Quarter Results on November 6, 2024
04:00pm, Wednesday, 23'rd Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 6, 2024 at 4:0
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
07:30am, Wednesday, 16'th Oct 2024
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commer
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 03'rd Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate of
